muscarinic 3 antagonist/beta 2 agonist (Teijin Pharma)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namemuscarinic 3 antagonist/beta 2 agonist (Teijin Pharma)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMuscarinic acetylcholine receptor M3 antagonistsBeta-2 adrenergic receptor agonists
TargetsMuscarinic acetylcholine receptor M3Beta-2 adrenergic receptor
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTeijin Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTeijin Pharma
Active IndicationsN/A
Inactive IndicationsPulmonary Disease, Chronic ObstructiveAsthma

Other Information

ATC CodeN/A
Related LinksN/A